ELI LILLY AND COMPANY Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- ELI LILLY AND COMPANY treasury stock, value, acquired, cost method for the quarter ending 2026-03-31 was $2.30B.
- ELI LILLY AND COMPANY treasury stock, value, acquired, cost method for the quarter ending 2018-03-31 was $1.10B, a 1733.33% increase year-over-year.
- ELI LILLY AND COMPANY treasury stock, value, acquired, cost method for the quarter ending 2017-12-31 was $99.90M, a 58.38% decline year-over-year.
- ELI LILLY AND COMPANY treasury stock, value, acquired, cost method for the quarter ending 2017-09-30 was $0.00.
- ELI LILLY AND COMPANY treasury stock, value, acquired, cost method for fiscal 2025 was $4.10B, a 64.00% increase from fiscal 2024.
- ELI LILLY AND COMPANY treasury stock, value, acquired, cost method for fiscal 2024 was $2.50B, a 233.33% increase from fiscal 2023.
- ELI LILLY AND COMPANY treasury stock, value, acquired, cost method for fiscal 2023 was $750.00M, a 50.00% decline from fiscal 2022.
- ELI LILLY AND COMPANY treasury stock, value, acquired, cost method for fiscal 2022 was $1.50B, a 20.00% increase from fiscal 2021.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2026-03-31 | $2.30B 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $4.10B 10-K · filed 2026-02-12 | |
| 2024-12-31 | $2.50B 10-K · filed 2026-02-12 | |
| 2023-12-31 | $750.00M 10-K · filed 2026-02-12 | |
| 2022-12-31 | $1.50B 10-K · filed 2025-02-19 | |
| 2021-12-31 | $1.25B 10-K · filed 2024-02-21 | |
| 2020-12-31 | $500.00M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $4.40B 10-K · filed 2022-02-23 | |
| 2018-12-31 | $4.15B 10-K · filed 2021-02-17 | |
| 2018-03-31 | $1.10B 10-Q · filed 2018-04-27 | $1.40B derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | $99.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $359.80M 10-K · filed 2020-02-19 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-27 | $499.90M derived: sum of 4 quarters · filed 2019-10-24 |
| 2017-06-30 | $199.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $499.90M derived: sum of 4 quarters · filed 2019-10-24 |
| 2017-03-31 | $60.00M 10-Q · filed 2018-04-27 | $300.00M derived: sum of 4 quarters · filed 2019-10-24 |
| 2016-12-31 | $240.00M derived: 8-K 12 month − 10-Q 9 month · filed 2019-10-24 | $540.10M 8-K · filed 2019-10-24 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-27 | $553.00M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $614.10M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-03-31 | $300.10M 10-Q · filed 2017-05-01 | $739.00M derived: sum of 4 quarters · filed 2018-02-20 |
| 2015-12-31 | $252.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $749.50M 10-K · filed 2018-02-20 |
| 2015-09-30 | $61.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-28 | $796.60M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $124.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $1.04B derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $310.60M 10-Q · filed 2016-04-29 | $1.06B derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $300.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $800.00M 10-K · filed 2017-02-21 |
| 2014-09-30 | $300.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | |
| 2014-06-30 | $145.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | |
| 2014-03-31 | $55.00M 10-Q · filed 2015-04-30 | |
| 2013-12-31 | $1.60B 10-K · filed 2016-02-19 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-28 | |
| 2013-03-31 | $1.10B 10-Q · filed 2014-10-29 | |
| 2012-12-31 | $819.20M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $819.20M 10-K · filed 2015-02-19 |
| 2006-12-31 | $2.58B 10-Q · filed 2012-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |